ArticleTranslational oncology2026
The tumor-microenvironment-associated prognostic gene TIGIT promotes malignant phenotypes in esophageal carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown that tumor immune microenvironment related markers are associated with tumor prognosis. However, few studies have explored the prognostic value of tumor cell surface biomarkers (e.g., CD8, TIM3, PD-L1, LAG3, CD163, and TIGIT) in resectable ESCC.
methodsWe retrospectively analyzed 69 ESCC patients who underwent complete resection at Zhejiang Cancer Hospital. Using multiplex immunofluorescence histochemistry, we evaluated the expression of CD8, TIM3, PD-L1, LAG3, CD163, and TIGIT in tumor and immune microenvironments and their associations with clinical outcomes. Triple-color immunofluorescence confirmed TIGIT expression in ESCC tissues. Functional roles of TIGIT were further investigated via RNA-seq, real-time PCR, WB, CCK-8 assays, transwell assays, and flow cytometry.
resultsThe median follow-up was 47.7 months. High expression was most frequent for CD8 (52.2%), followed by TIM3 (29.0%), PD-L1 (17.4%), LAG3 (24.6%), TIGIT (20.3%), and CD163 (14.5%). Median DFS was 17.4 months and OS was 26.8 months. Higher TIGIT expression correlated with shorter DFS and OS. Stratification by TIGIT-to-PAN-CK ratio confirmed that higher tumor-cell TIGIT was an unfavorable prognostic indicator. Functional analyses showed that TIGIT knockdown reduced ESCC cell migration, invasion, and proliferation, and altered cell cycle distribution with S-phase accumulation. RNA-sequencing implicated cytokine-receptor interactions and the JAK-STAT signaling axis in TIGIT-mediated functions.
conclusionsTIGIT, along with PD-L1 and CD163, is a potential prognostic marker for resectable ESCC. TIGIT is not only expressed in immune cells but also in ESCC tumor cells, suggesting its potential as a biomarker and therapeutic target. Further mechanistic studies are warranted to elucidate the downstream signaling pathways and validate the mechanisms of TIGIT in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.